Q4 2024 Immunocore Holdings PLC Earnings Call Transcript
Key Points
- Immunocore Holdings PLC (IMCR) reported a 30% year-on-year revenue growth, reaching $310 million in 2024.
- KIMMTRAK sales showed strong performance with a 5% increase in Q4 compared to Q3, and a 34% year-on-year growth in the US.
- The company has advanced its clinical pipeline with three ongoing Phase 3 trials and initiated two Phase 1 trials in 2024.
- KIMMTRAK has been launched in 24 countries, with recent approvals in Brazil, and has achieved over 80% market share in HLA-A*02:01 positive patients.
- Immunocore's R&D efforts have expanded into new therapeutic areas, including autoimmune diseases, with promising candidates targeting Type 1 diabetes and atopic dermatitis.
- The reimbursement environment in Europe remains challenging, affecting revenue recognition and price negotiations.
- SG&A and R&D expenses have increased compared to 2023, primarily due to investments in clinical trials and business operations.
- The company faces uncertainties in achieving viral control in its HIV program, as no therapy has reliably demonstrated this yet.
- There is a need for further data to confirm the efficacy and safety of new treatments in infectious diseases and autoimmune settings.
- Market penetration for KIMMTRAK in the US is at 65%, indicating limited headroom for growth in this market.
Greetings and welcome to the Immunocore conference call and webcast. (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce Clayton Robertson, Head of Investor Relations. Thank you. You may begin.
Thank you. Good morning and good afternoon. Thank you for joining us on our 4Q and full year 2024 earnings call. During today's call, we will make some forward-looking statements which are qualified by our safe harbor provision under the Private Securities Litigation Reform Act of 1995.
Please note that actual results can vary materially from those indicated by these forward-looking statements, including those discussed in our filings with the SEC. On today's call, I'm joined by Bahija Jallal, CEO of Immunocore, who will share a strategy update. Then Ralph Torbay, Head of Commercial, will review our full year '24 KIMMTRAK sales and KIMMTRAK's life cycle management plans. David Berman, our Head of R&D, will provide some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
